AFTX-201: A next-generation, one-time genetic medicine for BAG3 DCM
Date: June 10, 2026
Time: 6:00pm EDT
Please join us for an educational webinar about AFTX-201, a next generation, investigational gene therapy that has been designed as a one-time treatment for patients with dilated cardiomyopathy due to mutations in the BAG3 gene. We’ll talk about the journey of Affinia Therapeutics and AFTX-201 to the first-in-human clinical trial.
We’ll also share an overview of the UPBEAT© trial, a multi-center, open-label, Phase 1b/Phase 2, dose-exploration, and dose-expansion trial of AFTX-201 for patients with dilated cardiomyopathy due to mutations in BAG3. The goal of the study is to help researchers better understand the safety and potential for efficacy of AFTX-201. We’ll explain what taking part may look like, who may be eligible, and how to learn more.
There will also be a Question-and-Answer section at the end of the webinar to answer any questions that you might have.
If you, a family member, or someone that you know has dilated cardiomyopathy due to mutations in the BAG3 gene you should attend. We also encourage all Health Care Providers that might have patients with mutations in the BAG3 gene to join this webinar.
Presenters:
Hideo Makimura, M.D., Ph.D.
Chief Medical Officer
Affinia Therapeutics
Arvind Bhimaraj, M.D.
Advanced Heart Failure Cardiologist and Physician Scientist
Principal Investigator, UPBEAT© trial
Houston Methodist Hospital
